He's seen results from the ENID patients. I would assume he's seen similar trends within the double-blinded study and can extrapolate similar trends from patients that weren't blinded from a study.
Although the placebo effect is a very real thing, I doubt with CV19 you'd see a reduction of IL6 and other inflammatory mediators from just the placebo.